Related references
Note: Only part of the references are listed.Cost-effectiveness of 10-Year Risk Thresholds for Initiation of Statin Therapy for Primary Prevention of Cardiovascular Disease
Ankur Pandya et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)
Guideline-Based Statin Eligibility, Coronary Artery Calcification, and Cardiovascular Events
Amit Pursnani et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)
More Than a Billion People Taking Statins? Potential Implications of the New Cardiovascular Guidelines
John P. A. Ioannidis
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2014)
2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines
Neil J. Stone et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2014)
Application of New Cholesterol Guidelines to a Population-Based Sample
Michael J. Pencina et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Comparative effectiveness of rosuvastatin versus simvastatin in primary prevention among new users: a cohort study in the French national health insurance database
Anke Neumann et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2014)
Budget Impact Analysis Principles of Good Practice: Report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force
Sean D. Sullivan et al.
VALUE IN HEALTH (2014)
Nation-scale adoption of new medicines by doctors: an application of the Bass diffusion model
Adam G. Dunn et al.
BMC HEALTH SERVICES RESEARCH (2012)
The Cost-Effectiveness of C-Reactive Protein Testing and Rosuvastatin Treatment for Patients With Normal Cholesterol Levels
Niteesh K. Choudhry et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2011)
Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey
Salim Yusuf et al.
LANCET (2011)
DIFFUSION OF INNOVATIONS IN HEALTH CARE: DOES THE DUAL MARKET PHENOMENON EXIST?
R. Arbel et al.
VALUE IN HEALTH (2011)
Meta-analysis of Comparative Efficacy of Increasing Dose of Atorvastatin Versus Rosuvastatin Versus Simvastatin on Lowering Levels of Atherogenic Lipids (from VOYAGER)
Stephen J. Nicholls et al.
AMERICAN JOURNAL OF CARDIOLOGY (2010)
Cost-effectiveness of statin therapy for vascular event prevention in adults with elevated C-reactive protein: implications of JUPITER
Julia F. Slejko et al.
CURRENT MEDICAL RESEARCH AND OPINION (2010)
Much Cheaper, Almost as Good: Decrementally Cost-Effective Medical Innovation
Aaron L. Nelson et al.
ANNALS OF INTERNAL MEDICINE (2009)
Number Needed to Treat With Rosuvastatin to Prevent First Cardiovascular Events and Death Among Men and Women With Low Low-Density Lipoprotein Cholesterol and Elevated High-Sensitivity C-Reactive Protein Justification for the Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)
Paul M. Ridker et al.
CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES (2009)
Lipidomic approach to evaluate rosuvastatin and atorvastatin at various dosages: investigating differential effects among statins
Sandrin C. Bergheanu et al.
CURRENT MEDICAL RESEARCH AND OPINION (2008)
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Paul M. Ridker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
When does the majority become a majority? Empirical analysis of the time at which main market adopters purchase the bulk of our sales
Eitan Muller et al.
TECHNOLOGICAL FORECASTING AND SOCIAL CHANGE (2006)
Are statins created equal? Evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease prevention
Z Zhou et al.
AMERICAN HEART JOURNAL (2006)
Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial
Haruo Nakamura et al.
LANCET (2006)
Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvalstaltin, and pravastatin across doses (STELLAR* trial)
PH Jones et al.
AMERICAN JOURNAL OF CARDIOLOGY (2003)
Share Paper
